World Ovarian Cancer Day – Insights from Board Advisor, Heather Hawkins
By Christine Filippis / May 8, 2025
Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins - ovarian cancer...
Read More
Cartherics appoints new Board Chair and Non-Executive Director
By Christine Filippis / April 16, 2025
Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director Melbourne, Australia, 16 April...
Read More
Cartherics strengthens scientific and manufacturing team
By Christine Filippis / March 20, 2025
Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams,...
Read More
Cartherics CEO discusses the future of cancer treatment in The Australian
By Christine Filippis / March 17, 2025
Cartherics’ CEO, Prof. Alan Trounson, recently contributed to an insightful article in The Weekend Australian, exploring the latest advancements in...
Read More
Cartherics comes together to raise awareness and shine a spotlight on ovarian cancer
By Christine Filippis / February 27, 2025
As Ovarian Cancer Awareness Month draws to a close, the Cartherics team gathered for an afternoon dedicated to raising awareness...
Read More
iPSC-Derived NK Cells and the Future of Immunotherapy
By Christine Filippis / February 14, 2025
Induced pluripotent stem cell (iPSC)-derived NK cells are revolutionising cancer immunotherapy by offering a scalable and reliable source of immune...
Read More
Cartherics presents at Australia and New Zealand’s Biologics Festival
By Christine Filippis / February 7, 2025
Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3rd ANZ Biologics Festival at Crown Promenade in Melbourne....
Read More
The Power and Potential of Natural Killer Cell Therapies: A New Awakening
By Christine Filippis / December 20, 2024
In a recent article published in CGTLive, Cartherics’ Prof. Alan Trounson, Karl Trounson, Dr Walid Azar and Prof. Richard Boyd,...
Read More
Cartherics awarded US$300K G-Rex grant to accelerate clinical manufacturing of CAR-NK cell therapy
By Christine Filippis / December 18, 2024
Cartherics has received a US$300K G-Rex grant to support its ‘in house’ manufacturing program Funding will enable Cartherics to generate...
Read More
Message from the CEO
By Christine Filippis / December 16, 2024
As we reflect on 2024, it's clear that this year has been a defining chapter in Cartherics' 10-year history. We've...
Read More
BioSpectrum Asia: “Moving forward, cancer may not be a death threat but a manageable disease with strong control”
By Christine Filippis / November 6, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for...
Read More
Cartherics is “Frocking Up” this month to support ovarian cancer research
By Christine Filippis / October 30, 2024
Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival...
Read More
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs
By Christine Filippis / October 1, 2024
Financing round was significantly oversubscribed by existing investors and new private investors. Funding will enable the Company to progress clinical...
Read More
Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions
By Christine Filippis / September 20, 2024
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar...
Read More
Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment
By Christine Filippis / August 8, 2024
Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating...
Read More
